Regulatory Scrutiny Meets Analyst Optimism in Applovin’s Market Drama

Applovin shares are navigating turbulent waters as conflicting market forces create a volatile trading environment. While a newly announced regulatory investigation has triggered significant selling pressure, prominent financial analysts are simultaneously expressing strong confidence in the company’s fundamental performance and strategic direction.

Strong Financial Performance Amid Uncertainty

The foundation for analyst optimism lies in Applovin’s impressive second-quarter 2025 results. The company reported explosive revenue growth of 77%, reaching $1.26 billion. Even more strikingly, net profit doubled to $819.5 million, demonstrating robust operational efficiency despite emerging challenges.

Several key market factors are currently influencing investor sentiment:
* Ongoing SEC investigation into data collection practices
* Inclusion in the S&P 500 index during September, triggering 7% after-hours gains
* Introduction of the Axon Ads Manager targeting smaller advertisers
* Multiple positive analyst ratings and price target increases

Regulatory Pressure Intensifies

On October 6, the U.S. Securities and Exchange Commission initiated a formal investigation into Applovin’s business practices. The probe focuses on allegations that the company may have violated service agreements with platform partners to facilitate more targeted advertising capabilities. Market reaction was immediate and severe, with shares plunging 14% following the announcement.

Should investors sell immediately? Or is it worth buying Applovin?

The regulatory scrutiny appears to have been prompted by a combination of whistleblower complaints and reports from short-sellers, significantly increasing compliance pressure on the mobile technology firm.

Wall Street Maintains Bullish Stance

Contrasting sharply with regulatory concerns, financial institutions have demonstrated remarkable confidence in Applovin’s prospects. RBC Capital Markets initiated coverage with an “Outperform” rating, while Morgan Stanley raised its price target, citing significant potential in the company’s new Axon Ads Manager for non-gaming applications. Additional bullish commentary emerged from both Jefferies and Benchmark, creating a clear divergence between regulatory headlines and analyst sentiment.

Investors now face a critical evaluation: do the demonstrated growth metrics and strategic advancements outweigh the substantial regulatory risks? The company’s expansion into non-gaming segments is widely viewed as crucial for sustaining its impressive growth trajectory moving forward.